SMS Pharmaceuticals shares gained nearly 18% on the back of U.S. Food and Drug Administration approving associate company VKT Pharma’s reformulated Ranitidine.
The approval also marks the re-entry of the important acid-reducing medication into the U.S. market after a five-year absence. The U.S. FDA has approved VKT Pharma’s reformulated Ranitidine tablets in two strengths, 150 mg and 300 mg.
SMS Pharma shares closed 17.74% higher at ₹322.60 apiece on the BSE on Wednesday.
The U.S. FDA, announcing the decision, said the approval follows extensive safety testing and manufacturing improvements that address previous concerns about N-nitrosodimethylamine (NDMA) impurity formation during the product’s shelf-life. The move is expected to increase access to the medication for patients who rely on it for various health conditions.
Published – November 26, 2025 10:08 pm IST
Source: https://www.thehindu.com/business/sms-pharma-gains-18-on-us-fda-nod-for-reformulated-ranitidine-of-associate-firm/article70326910.ece
